Last reviewed · How we verify
NCT04284215
Efficacy and Safety of Albumin Paclitaxel Combined With Cisplatin Chemoradiotherapy for Non-resectable Stage III NSCLC
NA trial testing Albumin paclitaxel combined with cisplatin in Efficacy and Safety in 68 participants. Status unknown.
30 September 2021
Quick facts
| Lead sponsor | Guizhou Medical University |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 68 |
| Start date | 1 September 2019 |
| Primary completion | 30 September 2021 |
| Estimated completion | 30 October 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- Albumin paclitaxel combined with cisplatin — full drug profile →
Conditions studied
- Efficacy and Safety — all drugs for Efficacy and Safety →
Sponsor
Guizhou Medical University
Who can join
Adults 18 to 80, any sex, with Efficacy and Safety. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Non-resectable stage III non-small cell lung cancer is recommended for concurrent chemoradiotherapy. Paclitaxel and platinum are commonly used in chemotherapy regimens. The aim of this study was to investigate whether paclitaxel albumin combined with cisplatin combined with three-dimensional primary radiotherapy could improve short-term efficacy, local progression-free survival, and reduce treatment-related toxicity. To determine whether paclitaxel albumin combined with cisplatin regimen can be used as a first-line treatment for stage III non-small cell lung cancer with concurrent primary thoracic radiotherapy
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04284215
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Efficacy and Safety
Currently open trials in the same condition.
- NCT07256522 — Comparative Evaluation of Finger Splint, Paraffin, and Peloidotherapy Interventions in the Management of Trigger Finger · NA · recruiting
- NCT07053137 — A Comparative Study of the Efficacy and Safety of Telitacicept and Belimumab in the Treatment of Systemic Lupus Erythema · active not recruiting
- NCT06732427 — Clinical Study of Fospropofol Disodium for Injection in the Painless Endoscopic Diagnosis and Treatment · NA · recruiting
- NCT07362693 — A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA · recruiting
- NCT06826885 — Safety and Efficacy of IMPT or IMRT for Breast Cancer · recruiting
Other Guizhou Medical University trials
Trials by the same sponsor.
- NCT07462728 — Phase III, Multicenter, Randomized Controlled Clinical Study of Three-Dimensional Radiotherapy for Primary Tumors in Non · NA · not yet recruiting
- NCT07025863 — Intervention Program for Alarm Fatigue in NICU Nurses Based on ABC-X Model · NA · enrolling by invitation
- NCT06014450 — Prophylactic Cranial Irradiation Versus Observation in Stage IV NSCLC Randomized Controlled Clinical Study · NA · unknown
- NCT05252065 — Cardiac Substructure Radiation Dose and Early Clinical Monitoring of Stage N2-3 Non-Small Cell Lung Cancer · unknown
- NCT05176067 — Randomized Controlled Clinical Study of Drug Therapy Combined With Thoracic Radiotherapy for Non-oligometastatic NSCLC · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04284215 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guizhou Medical University
- Last refreshed: 25 February 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04284215.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing